2 results
Approved WMORecruiting
Primary objective: To determine the efficacy of Sunitinib on the progression-free survival at 12 months in subjects with progressive malignant pheochromocytoma and paraganglioma treated with sunitinib at a starting dose of 37.5 mg daily (continuous…
Approved WMORecruiting
We aim to compare the effectiveness of sildenafil versus placebo in achieving healthy perinatal survival, in women with singleton pregnancies with severe fetal growth restriction of placental origin.